Multiple Product Candidates Expected to Advance to Clinic

Sutro Biopharma is working independently and with partners to develop novel cancer therapies, including antibody-drug conjugates, bispecific antibodies, and cytokine-based therapeutics targeting immuno-oncology and autoimmune pathways.

Our Pipeline of Product Candidates and Programs, all based on our proprietary XpressCF Platform, are summarized in the chart below: